Clinical Trials Directory

Trials / Completed

CompletedNCT03226132

Improving Sleep to Reduce Risk for Substance Use Disorder

Biobehavioral Mechanisms Underlying Improving Sleep to Reduce Risk for Substance Use Disorder

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
73 (actual)
Sponsor
Florida State University · Academic / Other
Sex
All
Age
18 Years – 30 Years
Healthy volunteers
Not accepted

Summary

Substance use disorders (SUDs) are a prevalent and impairing condition, particularly among trauma exposed individuals. The current proposal aims to address the critical need for targeted direct SUD prevention in this population by intervening on a novel, malleable risk factor for SUD common among trauma-exposed individuals: sleep disturbance. Sleep disturbance prospectively predicts the development of SUD and may confer risk for SUD by increasing stress reactivity, decreasing decision-making abilities, and ultimately promoting substance use to relieve negative affect, a core etiological factor in SUD. However, to our knowledge, no experimental studies have determined whether improving sleep leads to reductions in SUD risk. As such, the current study will use a randomized controlled trial design to test the effects of brief behavioral treatment for insomnia (BBTI) against a waitlist control among a sample of trauma-exposed young adults with poor sleep and risk for SUD (N = 60). We aim to determine the direct and indirect effects of condition (BBTI vs. waitlist control) on SUD symptoms, substance use-related problems, coping motives, and posttraumatic stress symptoms through improvements in sleep. Furthermore, we will test direct and indirect effects of condition on theoretically proposed mechanisms underlying the association between sleep disturbance and SUD risk (i.e., stress reactivity, cravings in response to stress).

Conditions

Interventions

TypeNameDescription
BEHAVIORALBrief Behavioral Therapy for InsomniaBrief Behavioral Therapy for Insomnia
BEHAVIORALRepeated ContactRepeated Contact

Timeline

Start date
2017-08-20
Primary completion
2018-09-01
Completion
2018-09-01
First posted
2017-07-21
Last updated
2021-02-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03226132. Inclusion in this directory is not an endorsement.